Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience

Contributed by: Business Wire

Logo

Images

Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Nature Neuroscience.

Business Wire embedded0

Tags

Research

Technology

Clinical Trials

Health Technology

Software

Other Health

Biotechnology

Health

Science

Artificial Intelligence

ALEMBIC

More Like This

Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial

Marco Quarta (right), Rubedo Life Sciences CEO and Co-Founder, notarizes the incorporation of Rubedo's European Headquarters in Milan (Photo: Business Wire)

Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial

Rubedo Life Sciences scientists (Photo: Business Wire)

Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging

PR Newswire associated0

Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board

PR Newswire associated0

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities